Czechia· CZ-0286409
EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE VIATRIS
A emtricitabine, tenofovir alafenamide and rilpivirine product containing emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide fumarate, registered in Czechia by VIATRIS LIMITED, Dublin. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Emtricitabine, tenofovir alafenamide and rilpivirine is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR19 (emtricitabine, tenofovir alafenamide and rilpivirine), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Emtricitabine, tenofovir alafenamide and rilpivirine · ATC J05AR19
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE + TENOFOVIR ALAFENAMIDE FUMARATE
- Manufacturer
- VIATRIS LIMITED, Dublin
- Country
- Czechia (CZ)
- ATC code
- J05AR19
- ATC class
- Emtricitabine, tenofovir alafenamide and rilpivirine
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Emtricitabine, tenofovir alafenamide and rilpivirine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Ltd
- FinlandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Limited
- SwedenEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg Filmdragerad tablettViatris Limited
- SpainEMTRICITABINA/RILPIVIRINA/TENOFOVIR ALAFENAMIDA VIATRIS 200 MG/25 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGViatris Limited
- IcelandEmtricitabine/Rilpivirine/Tenofovir Alafenamide ViatrisViatris Limited
- IrelandEmtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris 200 mg/25 mg/25 mg film-coated tabletsViatris Limited
- NorwayOdefseyAbacus Medicine A/S
- United StatesODEFSEYGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
- Liechtenstein · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
- Norway · Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris, Odefsey
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/832c251a-b212-4642-9876-e00b7a0c6a83 GET /v1/drugs/832c251a-b212-4642-9876-e00b7a0c6a83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "200MG/25MG/25MG",
"pack_size": "90",
"substance": "EMTRICITABINE + RILPIVIRINE HYDROCHLORIDE + TENOFOVIR ALAFENAMIDE FUMARATE",
"cz_kod_sukl": "0286409",
"product_type": "CH",
"substance_codes": "15579,17690,20936",
"registration_state": "R",
"registration_number": "EU/1/25/1966/006"
}See everything about emtricitabine, tenofovir alafenamide and rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.